Composition and method for enhancing fibrinolysis
US6114506A · kind A · utility
4Cited by
23References
8Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Sep 19, 1997 |
| Grant date | Sep 5, 2000 |
| Priority date | — |
| Expiry date | Sep 19, 2017 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2319/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to a novel alpha-2-antiplasmin-binding molecules and treatment for pulmonary embolism, myocardial infarction, thrombosis or stroke in a patient which comprises administering an alpha-2-antiplasmin-binding molecule capable of preventing inhibition of plasmin by endogenous alpha-2-antiplasmin. The invention also relates to a treatment for pulmonary embolism, myocardial infarction, thrombosis or stroke in a patient comprising coadministrating an alpha-2-antiplasmin-binding molecule of the invention together with a thrombolytic agent.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.